Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$97.28 USD

97.28
3,746,804

+2.16 (2.27%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $97.31 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (199 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics

The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and Schlumberger

Novartis, American Express, ConocoPhillips, Netflix and Schlumberger are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Novartis, American Express & ConocoPhillips

Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP).

Ekta Bagri headshot

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Novartis (NVS) to Undertake Job Cuts in Development Department

Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.

Novartis (NVS) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day.

Novartis (NVS) Declines More Than Market: Some Information for Investors

In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.

Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know

Zacks.com users have recently been watching Novartis (NVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know

Novartis (NVS) closed at $95.88 in the latest trading session, marking a +0.64% move from the prior day.

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.

Novartis (NVS) Declines More Than Market: Some Information for Investors

In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.

Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know

In the most recent trading session, Novartis (NVS) closed at $96.32, indicating a +0.42% shift from the previous trading day.

Novartis (NVS) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.

Here is What to Know Beyond Why Novartis AG (NVS) is a Trending Stock

Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Novartis (NVS) Stock Dips While Market Gains: Key Facts

In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.

Novartis (NVS) Advances While Market Declines: Some Information for Investors

Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.

Novartis (NVS) Gains As Market Dips: What You Should Know

In the latest trading session, Novartis (NVS) closed at $102.10, marking a +0.13% move from the previous day.

Is Trending Stock Novartis AG (NVS) a Buy Now?

Novartis (NVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here's Why Novartis (NVS) Fell More Than Broader Market

Novartis (NVS) reachead $102.22 at the closing of the latest trading day, reflecting a -0.9% change compared to its last close.